PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsbasal cell carcinoma
MeSH D002280 - basal cell carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D002277:Carcinoma
$
Success rate
D018295:Basal cell neoplasms
$
Success rate
D002280: 
Basal cell carcinoma
$
Success rate
D001478:Basal cell nevus syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaFluorouracil Adrucil  1991-10-18   
Fluorouracil Fluorouracil  2000-01-27   
Novast LaboratoriesFluorouracil Fluorouracil  2019-12-12   
PadagisImiquimod Imiquimod  2010-09-07   
Taro PharmaceuticalFluorouracil Fluorouracil  2003-11-05   
Imiquimod Imiquimod  2011-04-15   
Glenmark PharmaceuticalsImiquimod Imiquimod  2012-03-06   
MylanFluorouracil Fluorouracil  2015-04-20   
SandozFluorouracil Fluorouracil  2011-05-02   
3MImiquimod Zartra  1998-09-18   
Bausch Health CompaniesImiquimod Aldara 2024-04-01 1997-02-27   
Fluorouracil Carac  2000-10-27   
Fluorouracil Efudex  1982-01-01   
Imiquimod Zyclara 2029-08-18 2010-03-25   
Cosette Pharmaceuticals Imiquimod Imiquimod  2011-04-18   
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
48%
11/23
Phase 2
8%
1/13
Phase 3
100%
9/9
Approved: 6Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Taro Pharmaceutical
Bausch Health Companies
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use